Pharmaceutical

China NMPA grants approval for GenFleet’s fulzerasib to treat lung cancer

China has granted approval for GenFleet Therapeutics’ fulzerasib for advanced non-small cell lung cancer (NSCLC).

Aug 27, 2024 - 04:00
China NMPA grants approval for GenFleet’s fulzerasib to treat lung cancer
China has granted approval for GenFleet Therapeutics’ fulzerasib for advanced non-small cell lung cancer (NSCLC).
Read the original article

Tags:

Previous Article

Invenra’s antibody gains US FDA designations for neuroblastoma treatment

Next Article

Janssen’s BALVERSA receives EC approval for metastatic urothelial carcinoma

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Biogen’s sticky situation, Wegovy’s risks, & biotech insider trading

Biogen’s sticky situation, Wegovy’s risks, & biotech in...

Jul 28, 2023

Syros Pharmaceuticals gets grant for CDK7 inhibitors for treating cancer and other diseases

Syros Pharmaceuticals gets grant for CDK7 inhibitors fo...

Jun 12, 2024

House GOP inquiry over gain-of-function research targets a scientific giant

House GOP inquiry over gain-of-function research target...

Jun 22, 2023